# Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).

> **NCT01116219** · PHASE2 · COMPLETED · sponsor: **Swiss Cancer Institute** · enrollment: 149 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab, erlotinib
- **DRUG:** bevacizumab, pemetrexed, cisplatin

## Key facts

- **NCT ID:** NCT01116219
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2014-07
- **Final completion:** 2016-05
- **Target enrollment:** 149 (ESTIMATED)
- **Last updated:** 2019-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01116219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01116219, "Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT01116219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*